LJUBLJANA (Slovenia), November 17 (SeeNews) – Slovenian pharmaceutical company Krka [LJE:KRKG] said on Thursday that its consolidated net profit for the first nine months of 2022 rose 26% to 301.7 million euros ($313.2 million).
In the January-September period, consolidated sales revenues increased by 6 percent to 1.242 billion euros on an annual basis, of which 94 percent of total sales were abroad, Krka wrote in the announcement on the preliminary results of the group’s operations in the nine months.
Compared to the previous year, the nine-month operating profit (EBIT) of the Krka Group decreased by 14 percent to 233.8 million euros, and the operating profit before depreciation (EBITDA) by 11 percent to 314.2 million euros.
In the first nine months of 2022, the Krka Group allocated EUR 74.9 million for investments, of which EUR 53.1 million went to the controlling company.
Krka announced that 11,489 employees were employed in the group at the end of September.
Eastern Europe generated the most sales in the group – EUR 414.1 million, which is 4% more than in the same period last year, and product sales in Russia, Krka’s largest single market, increased by 5% to EUR 251.3 million.
Sales in Central Europe increased by 3% to EUR 280.9 million between January and September, followed by sales of EUR 242.4 million in Western Europe, up 6% year-on-year.
In the period under review, sales in South-Eastern Europe increased by 5 percent to 172.8 million euros, in Slovenia by 12 percent to 77.2 million euros, and sales in the segment of overseas markets by 18 percent to 49.1 million euros.
($ = 0.9634 euros)
KRKA dd is one of the largest companies in SE, for more information see Top 100 companies